Indrajeet Singh

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.5K citations

Hematological Malignancy, Cell Therapy, Immunotherapy +11

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Deepu Madduri, Saad Z. Usmani, Sundar Jagannath et al. · Blood · 2019 · 119 citations

Fluid Shear Induces Conformation Change in Human Blood Protein von Willebrand Factor in Solution

Indrajeet Singh, Efrosyni Themistou, Lionel Porcar et al. · Biophysical Journal · 2009 · 98 citations · Full text

Mechanobiology, Engineering, Immunology +7

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Pau Montesinos, Gail J. Roboz, Claude‐Eric Bulabois et al. · Leukemia · 2020 · 96 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +5

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Deepu Madduri, Jesús G. Berdeja, Saad Z. Usmani et al. · Blood · 2020 · 92 citations